GWMIA
NTLA icon

Global Wealth Management Investment Advisory’s Intellia Therapeutics NTLA Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed -$3K – 696
2019
Q2 		$3K Hold
200
– – ﹤0.01% 506
2019
Q1 		$3K Hold
200
– – ﹤0.01% 500
2018
Q4 		$3K Buy
+200
New +$3.72K ﹤0.01% 542

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Global Wealth Management Investment Advisory's NTLA Position: Q3 2019 in Review

Global Wealth Management Investment Advisory sold out of Intellia Therapeutics (NTLA) in Q3 2019, closing a stake of 200 shares — an estimated $3K sold.

Global Wealth Management Investment Advisory first reported a position in NTLA in Q4 2018 and held it in 3 quarters. The position peaked at $3K in Q2 2019. 136 funds tracked by Wall St. Rank hold NTLA as of Q3 2019.

  • Global Wealth Management Investment Advisory reported no remaining Intellia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Global Wealth Management Investment Advisory sold 200 Intellia Therapeutics shares in Q3 2019, an estimated $3K.
  • Global Wealth Management Investment Advisory first reported a position in Intellia Therapeutics in Q4 2018 and held it in 3 quarters.
  • Global Wealth Management Investment Advisory's Intellia Therapeutics position peaked at $3K in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2019.

Based on Global Wealth Management Investment Advisory's 13F filing for Q3 2019, filed 14 Nov 2019.